Trial · NCT00537381
Results by group34
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 34
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-Free Survival (PFS) | Docetaxel + Prednisone + Placebo | 336.0 | 95% Confidence Interval 266.0 to 477.0 | Days | |
| Progression-Free Survival (PFS) | Docetaxel + Prednisone + Intetumumab | 232.0 | 95% Confidence Interval 155.0 to 320.0 | Days | |
| Number of Participants With Best Overall Response (OR) | Docetaxel + Prednisone + Placebo | Complete Response | 1 | Participants | |
| Number of Participants With Best Overall Response (OR) | Docetaxel + Prednisone + Intetumumab | Complete Response | 0 | Participants | |
| Number of Participants With Best Overall Response (OR) | Docetaxel + Prednisone + Placebo | Partial Response | 9 | Participants | |
| Number of Participants With Best Overall Response (OR) | Docetaxel + Prednisone + Intetumumab | Partial Response | 8 | Participants | |
| Number of Participants With Prostate Specific Antigen (PSA) Response | Docetaxel + Prednisone + Placebo | 43 | Participants | ||
| Number of Participants With Prostate Specific Antigen (PSA) Response | Docetaxel + Prednisone + Intetumumab | 27 | Participants | ||
| Overall Survival | Docetaxel + Prednisone + Placebo | 626.0 | 95% Confidence Interval 532.0 to NA | Days | |
| Overall Survival | Docetaxel + Prednisone + Intetumumab | 522.0 | 95% Confidence Interval 418.0 to NA | Days | |
| Percent Change From Baseline in 'C-telopeptide of Type I Collagen (CTx)' Marker Concentration | Docetaxel + Prednisone + Placebo | Percent Change at Week 6 (n = 10, 48) | 1.45 | Standard Deviation 51.019 | Percent change |
| Percent Change From Baseline in 'C-telopeptide of Type I Collagen (CTx)' Marker Concentration | Docetaxel + Prednisone + Intetumumab | Percent Change at Week 6 (n = 10, 48) | -30.81 | Standard Deviation 42.091 | Percent change |
| Percent Change From Baseline in 'C-telopeptide of Type I Collagen (CTx)' Marker Concentration | Docetaxel + Prednisone + Placebo | Percent Change at Week 7 (n = 10, 54) | -11.58 | Standard Deviation 45.396 | Percent change |
| Percent Change From Baseline in 'C-telopeptide of Type I Collagen (CTx)' Marker Concentration | Docetaxel + Prednisone + Intetumumab | Percent Change at Week 7 (n = 10, 54) | -39.78 | Standard Deviation 32.437 | Percent change |
| Percent Change From Baseline in 'C-telopeptide of Type I Collagen (CTx)' Marker Concentration | Docetaxel + Prednisone + Placebo | Percent Change at Week 10 (n = 11, 51) | 2.39 | Standard Deviation 53.537 | Percent change |
| Percent Change From Baseline in 'C-telopeptide of Type I Collagen (CTx)' Marker Concentration | Docetaxel + Prednisone + Intetumumab | Percent Change at Week 10 (n = 11, 51) | -25.48 | Standard Deviation 122.178 | Percent change |
| Percent Change From Baseline in 'C-telopeptide of Type I Collagen (CTx)' Marker Concentration | Docetaxel + Prednisone + Placebo | Percent Change at Week 13 (n = 11, 41) | 5.22 | Standard Deviation 59.728 | Percent change |
| Percent Change From Baseline in 'C-telopeptide of Type I Collagen (CTx)' Marker Concentration | Docetaxel + Prednisone + Intetumumab | Percent Change at Week 13 (n = 11, 41) | -44.89 | Standard Deviation 40.941 | Percent change |
| Percent Change From Baseline in 'N-telopeptide of Type I Collagen (NTx)' Marker Concentration | Docetaxel + Prednisone + Placebo | Percent Change at Week 6 (n = 10, 48) | -0.77 | Standard Deviation 37.584 | Percent change |
| Percent Change From Baseline in 'N-telopeptide of Type I Collagen (NTx)' Marker Concentration | Docetaxel + Prednisone + Intetumumab | Percent Change at Week 6 (n = 10, 48) | -21.37 | Standard Deviation 47.747 | Percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00537381/results